10-Q: Autonomix Medical Reports Q3 2025 Results, Highlights Recent Financing and Reverse Stock Split

Autonomix Medical, a clinical-stage medical device company, announced its Q3 2025 financial results, detailing a recent public offering and a reverse stock split.

Summary

• Autonomix Medical, a pre-revenue, clinical-stage medical device company, reported its financial results for the quarter ended December 31, 2024.
• The company is focused on developing innovative technologies for sensing and treating disorders related to the peripheral nervous system.
• A reverse stock split at a ratio of 1-for-20 was approved and became effective on October 24, 2024.
• On November 22, 2024, the company entered into an underwriting agreement for a public offering, which closed on November 25, 2024, resulting in gross proceeds of approximately $10.0 million.
• The company incurred net losses of $8.2 million and $10.0 million for the nine months ended December 31, 2024 and 2023, respectively.
• As of December 31, 2024, the company had cash of $11.8 million and working capital of $9.7 million.
• The company estimates its current cash resources are sufficient to fund its operations into but not beyond the first calendar quarter of 2026.
• Additional financing of approximately $30 to $35 million will be required to fund operations to commercialization.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company successfully completed a financing, it is still operating at a loss and needs further capital to reach commercialization. The company's technology has potential, but it is still in the development stage.

Positives

• The successful completion of a public offering in November 2024, providing approximately $9.0 million in net cash proceeds.
• The company's first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
• Cash reserves of $11.8 million as of December 31, 2024.

Negatives

• The company has incurred net losses of $8.2 million for the nine months ended December 31, 2024.
• The company is a development stage company and there is no guarantee that the results of any trials will produce positive results or that the results will support our claims.
• The company estimates its current cash resources are sufficient to fund its operations into but not beyond the first calendar quarter of 2026.

Risks

• The company will need to raise additional capital to continue to execute its business plan.
• There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the company.
• A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the company's ability to meet its financial obligations.
• The company is inquiring into a request to issue 271,846 shares of common stock in connection with the reverse stock split and may face potential liability for failure to issue the shares if required.

Future Outlook

The company estimates its current cash resources are sufficient to fund its operations into but not beyond the first calendar quarter of 2026 and will require additional financing of approximately $30 to $35 million to fund operations to commercialization.

Management Comments

• The company is focused on developing innovative technologies for sensing and treating disorders related to the peripheral nervous system.
• The company is initially developing its technology for patients with pancreatic cancer, a condition that can cause debilitating pain and needs a more effective solution.
• The company believes its technology constitutes a platform with the potential to address dozens of indications in a range of areas including chronic pain management from all causes, hypertension, cardiovascular disease and a wide range of other nerve-related disorders.

Industry Context

The company operates in the medical device industry, specifically focusing on technologies for sensing and treating disorders related to the nervous system. This is a competitive field with established players and emerging companies developing innovative solutions for various indications, including pain management and cardiovascular diseases.

Comparison to Industry Standards

• The company's technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
• For the BSC Orion, the nearest device on the market, the metrics are 10uV for signal detection levels, and roughly 0.4mm by 0.5mm for the electrode dimensions.
• For the Autonomix device, the metrics are <1uV for signal detection levels and roughly 0.02mm by 0.03mm for the electrode dimensions.
• The differences in these metrics result in a calculation of 3,000 times greater sensitivity for the Autonomix device.

Management Changes

Related Party Transactions

• The company utilizes a consulting firm that is owned by the company's former Chief Financial Officer to provide accounting and financial reporting services.
• Members of the company's management/Board and an immediate family member of the company's management (related party), collectively purchased $0.5 million of the Bridge Offering.
• On July 7, 2023, the company and the Licensee entered into an Exclusive License Termination Agreement in exchange for the issuance, upon the closing of the company's initial public offering within one year of the agreements execution, of a warrant to purchase shares of the company for a variable number of shares.

Stakeholder Impact

• Shareholders: The reverse stock split and public offering will impact the value of their shares.
• Employees: The company is expanding its management team, which could create new opportunities.
• Customers: The company is developing new technologies that could improve the treatment of disorders related to the nervous system.
• Creditors: The company's ability to raise additional capital will impact its ability to meet its financial obligations.

Next Steps

• The company plans to continue developing its technology for patients with pancreatic cancer.
• The company plans to bring sensing and treatment together in a pivotal clinical trial to enable the commercial launch of its technology.
• The company will need to raise additional capital to meet its obligations and execute its business plan.

Key Dates

Keywords

Autonomix Medical, reverse stock split, public offering, financial results, medical device, warrants, clinical stage, financing, AMIX